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Pre-clinical studies suggest that the p38 MAPK signaling pathway plays a detrimental role in cardiac
remodeling, but its role in cardiac ﬁbroblast (CF) function is not well deﬁned. We aimed to identify
the p38 MAPK subtypes expressed by human CF, study their activation in response to proinﬂammatory
cytokines, and determine which subtypes were important for expression of speciﬁc cytokines and matrix
metalloproteinases (MMPs).
Quantitative real-time RT-PCR analysis of mRNA levels in human CF cultured from multiple patients
revealed a consistent pattern of expression with p38a being most abundant, followed by p38c, then
p38d and only low expression of p38b (3% of p38amRNA levels). Immunoblotting conﬁrmed marked pro-
tein expression of p38a, c and d, with little or no expression of p38b. Phospho-ELISA and combined
immunoprecipitation/immunoblotting techniques demonstrated that the proinﬂammatory cytokines
IL-1a and TNFa selectively activated p38a and p38c, but not p38d. Selective p38a siRNA gene silencing
reduced IL-1a-induced IL-6 and MMP-3 mRNA expression and protein secretion, without affecting IL-1a-
induced IL-1b and MMP-9 mRNA expression.
In conclusion, human CF express the a, c and d subtypes of p38 MAPK, and the a subtype is important
for IL-1a-induced IL-6 and MMP-3 expression in this cell type.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license. 1. Introduction
Cardiac ﬁbroblasts (CF) are the most populous cell type in the
heart and are intricately involved in the cardiac remodeling pro-
cess following myocardial infarction (MI) [1]. The tissue damage
caused by MI triggers an acute inﬂammatory response, with rap-
idly elevated levels of proinﬂammatory cytokines and chemokines
and inﬁltration of inﬂammatory cells [2,3]. This leads to formation
of granulation tissue which is rich in macrophages and myoﬁbro-
blasts, the latter being derived from both resident CF and non-res-
ident precursor cells [4]. Myoﬁbroblasts invade the infarct area and
degrade the extracellular matrix (ECM) via activation of members
of the matrix metalloproteinase (MMP) family of proteolytic en-
zymes to facilitate removal of cell and tissue debris and promote
neovascularization, prior to scar formation [2,3].
CF appear to be able to contribute to the inﬂammatory and
granulation phases of post-MI remodeling by secreting a range ofardiovascular and Diabetes
sity of Leeds, Leeds LS2 9JT,
r).
C-ND license. proinﬂammatory cytokines, chemokines and MMPs [1,5–8]. Inter-
leukin (IL)-6 is secreted by CF from multiple species [1] and con-
tributes to cardiac dysfunction by stimulating left ventricular
hypertrophy and ﬁbrosis [9]. CF can secrete several different
MMPs, including MMP-1, -2, -3, -9 and -10 [7,8]. MMP-3 is a broad
spectrum protease capable of cleaving several non-ﬁbrillar extra-
cellular matrix proteins as well as proteolytically activating other
MMPs (e.g. MMP-2 and -9). Although not particularly well studied
in the heart, MMP-3 appears to play a critical regulatory role in
early remodeling post-MI [10].
There is strong in vivo evidence that activation of the p38 mito-
gen-activated protein kinase (MAPK) family of stress-activated
kinases exacerbates myocardial injury following prolonged
ischemia [11]. Proinﬂammatory cytokines such as IL-1 and tumor
necrosis factor alpha (TNFa), which are potent stimuli for the
p38 MAPK pathway, are elevated in the infarcted heart and appear
to be detrimental for post-MI myocardial remodeling and progres-
sion to heart failure [12]. There are four known subtypes of p38
MAPK; p38a, p38b, and the more distantly related p38c and
p38d [13]. Each subtype is encoded by a separate gene and
their expression is restricted to speciﬁc tissues and cell types.
Importantly, much of the evidence supporting a role for p38 MAPK
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focused on its role in the cardiomyocyte, with comparatively little
focus on the CF [14]. However, there is evidence that p38
MAPK signaling differs between cardiac myocytes and ﬁbroblasts
in vivo [15].
The aims of this study were to identify the p38 MAPK subtypes
expressed by human CF, study their activation in response to pro-
inﬂammatory cytokines, and determine which subtypes were
important for mediating proinﬂammatory cytokine-induced in-
creases in cytokine and MMP expression.2. Materials and methods
2.1. Cell culture
Right atrial appendage biopsies from multiple patients under-
going elective coronary artery bypass surgery at the Leeds General
Inﬁrmary were obtained following local ethical committee ap-
proval and informed patient consent. Primary cultures of CF were
harvested, cultured and characterized as myoﬁbroblasts (alpha-
smooth muscle actin- and vimentin-positive) as we have described
previously [16–18]. Experiments were performed on early passage
cells (P3–P5) from several different patients (indicated by n num-
ber). Cells were serum-starved by culturing in serum-free medium
for 24 h before inclusion in experiments.
2.2. Immunoblotting
For p38 MAPK subtype expression analysis, whole cell homoge-
nates were prepared from serum-starved CF from 5 different pa-
tients as described previously [19]. Homogenates of human
saphenous vein endothelial cells, cultured as previously [20], were
prepared as additional controls. Equal amounts of protein (40 lg)
were resolved by SDS–PAGE and immunoblotting performed as de-
scribed previously [19] with p38 subtype-speciﬁc antibodies: rab-
bit monoclonal anti-p38a (#2371, Cell Signaling Technology), goat
polyclonal anti-p38b (#sc-6176, Santa Cruz Biotechnology), mouse
monoclonal anti-p38c (#MAB1347, R&D Systems) and rabbit poly-
clonal anti-p38d (#9214, Cell Signaling Technology). Expression of
b-actin was assessed as a loading control using a mouse monoclo-
nal anti-b-actin antibody (#ab8226, Abcam). Immunolabelled
bands were visualized by SuperSignal West Pico chemilumines-
cence kit (Perbio).
For signaling experiments, serum-starved CF were stimulated
with recombinant human IL-1a (Invitrogen), TNFa (Invitrogen) or
anisomycin (Sigma) in serum-free medium before preparing whole
cell homogenates. Activation of components of the p38 pathway
was determined by immunoblotting with phosphorylation state-
speciﬁc antibodies for p38 (Thr180/Tyr182), MAPKAPK2 (Thr334),
HSP27 (Ser82) and their corresponding expression antibodies (Cell
Signaling Technology).2.3. Quantitative RT-PCR
For p38 subtype expression analysis, cellular RNA was extracted
from serum-starved CF from 8 different patients and cDNA pre-
pared as described previously [21]. Real-time RT-PCR was per-
formed using an Applied Biosystems 7500 Real-Time PCR System
and intron-spanning human p38a (Hs00176247_m1), p38b
(Hs00177101_m1), p38c (Hs00268060_m1) and p38d
(Hs00559623_m1) primers and Taqman probes (Applied Biosys-
tems). Importantly, serial dilution of cDNA samples yielded compa-
rable efﬁciencies for these different primer/probe sets, allowing
meaningful comparison of expression levels between primer sets.Data are presented as percentage of GAPDH endogenous control
mRNA expression (Hs99999905_m1 primers) using the formula
2DCT  100.
For analysis of cytokine and MMP mRNA expression, cellular
RNA was extracted from cells at the end of the incubation period.
Real-time RT-PCR was performed using intron-spanning human
IL-6 (Hs00174131_m1), IL-1b (Hs00174097_m1), MMP-3
(Hs00233962_m1) and MMP-9 (Hs00234579_m1) primers and
Taqman probes (Applied Biosystems). Data are presented as per-
centage of GAPDH expression using the formula 2DCT  100.2.4. Measurement of p38 subtype phosphorylation
Serum-starved cells were stimulated for 30 min before
assessing phosphorylation of p38 MAPK subtypes within the
Thr⁄–Gly–Tyr⁄ activation site using two complementary methods;
a combined immunoprecipitation and immunoblotting (IP/IB)
assay and a phospho-ELISA. For the IP/IB assay, cells were extracted
in lysis buffer comprising 20 mM Tris (pH 7.5), 150 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyro-
phosphate, 1 mM glycerophosphate, 1 mM sodium orthovanadate,
1 lg/ml leupeptin. A pan phospho-speciﬁc p38 mouse monoclonal
antibody (#9216, Cell Signaling Technology) and protein-G
conjugated magnetic Dynabeads (Invitrogen) were employed to
immunoprecipitate phosphorylated p38 subtypes before immuno-
blotting with individual p38 subtype expression antibodies.
For p38 ELISA studies, cells were extracted in PBS (pH 7.4) con-
taining 1 mM EDTA, 6 M urea, 0.5% Triton X-100, 5 mM sodium
ﬂuoride, 10 lg/ml leupeptin, 10 lg/ml pepstatin, 100 lM PMSF,
3 lg/ml aprotinin, 2.5 mM sodium pyrophosphate, 1 mM sodium
orthovanadate. Colorimetric sandwich ELISAs (R&D Systems) were
then employed to measure phosphorylation of p38a, c and d,
according to the manufacturer’s instructions.2.5. Gene silencing
ON-TARGETplus human p38a siRNA (containing 4 different tar-
geted oligonucleotides) was purchased from Dharmacon. Cells
were plated at 100,000 per well in 6-well plates and 24 h later
were either mock-transfected (no siRNA) or transfected with
100 nM p38a siRNA using Lipofectamine 2000 (Invitrogen) accord-
ing to the manufacturer’s instructions. After 5 h, fresh growthmed-
ium was added to the cells before incubation for a further 4 days.
For the ﬁnal 16 h of the experiment, growth medium was replaced
with fresh serum-free medium. Cells were then treated with
appropriate stimuli before extracting RNA for RT-PCR or protein
for immunoblotting.2.6. IL-6 and MMP-3 ELISA
Conditioned media were collected 6 h (IL-6) or 24 h (MMP-3)
after cell treatment, centrifuged to remove any detached cells
and stored at 40 C for subsequent analysis. ELISAs were per-
formed according to the manufacturer’s instructions (R&D
Systems).2.7. Statistical analysis
Results are mean ± SEM with n representing the number of
experiments on cells from different patients. Data were analyzed
as ratios using either paired t-tests or repeated measures one-
way ANOVA followed by Newman-Keuls post hoc test (GraphPad
Prism software, www.graphpad.com). P < 0.05 was considered sta-
tistically signiﬁcant.
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3.1. Expression and activation of p38 MAPK subtypes
Expression of p38 subtypes in human CF was investigated by
quantitative real-time RT-PCR and immunoblotting. Analysis of
mRNA levels in cells from 8 different patients (Fig. 1A) revealed a
consistent pattern of expression with p38a being most abundant
(mean 2.0% of GAPDH mRNA levels), followed by p38c (0.5%),
p38d (0.12%) and p38b (0.06%). Immunoblotting of CF homoge-
nates from 5 further patients revealed marked protein expression
of p38a, c and d, but little or no p38b was detected (Fig. 1B). AsA                                           B
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and horizontal line is median). (B) Whole cell homogenates of CF (5 patients) or human
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downstream substrate MAPK-activated protein kinase 2 (MAP-
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as a positive control (Fig. 2A).
The ability of TNFa and IL-1a to stimulate p38a, c and d in CF
was investigated using a combined IP/IB method (Fig. 2B) and a
phospho-ELISA approach (Fig. 2C), which gave comparable results.
Both TNFa and IL-1a increased phosphorylation of p38a and p38c,
with IL-1a being the more potent stimulus (Fig. 2B and C). Neither
cytokine increased p38d phosphorylation above basal levels.A IL-6 mRNA MMP
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conditioned media from IL-1a treated cells. ⁄⁄P < 0.01 for effect of gene silencing.3.2. Effect of p38a gene silencing on signaling and expression of
cytokines and MMPs
We have previously demonstrated that TNFa and IL-1a potently
induce expression of a number of proinﬂammatory cytokines in
human CF (e.g. TNFa, IL-1a, IL-1b, IL-6, IL-8) [5,6,21], as well as
several MMPs (e.g. MMP-1, -3, -9 and -10) [8,22]. We also deter-
mined that IL-1a-induced IL-6 and MMP-3 mRNA expression was-3 mRNA p38αmRNA
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J.K. Sinﬁeld et al. / Biochemical and Biophysical Research Communications 430 (2013) 419–424 423inhibited by the p38a/b inhibitor SB203580, whereas IL-1a-in-
duced IL-1b and MMP-9 mRNA expression was not affected by
SB203580 [5,8]. This information, together with the knowledge of
subtype expression in CF, implicated p38a as the most likely sub-
type responsible for mediating IL-1a-induced IL-6 and MMP-3
mRNA expression in human CF. We therefore used a gene silencing
strategy to selectively reduce expression of p38a and investigated
the consequences at the level of cytokine and MMP expression.
Pilot experiments determined that p38a mRNA levels were re-
duced by 90% compared with mock-transfected cells 24 h after
transfection with appropriate siRNA oligonucleotides, followed
by reduced protein levels consistently observed 4 days after trans-
fection (data not shown). The effects of p38a gene silencing on
cytokine-induced signaling and expression of cytokines and MMPs
were therefore assessed 4 days after transfection with p38a siRNA.
At this time point, p38a mRNA levels remained signiﬁcantly re-
duced (by >50%) compared with mock-transfected cells (Fig. 3A)
and protein levels were reduced by >90% (Fig. 3B). The speciﬁcity
and selectivity of the gene silencing approach was conﬁrmed by
demonstrating that the three other p38 MAPK subtypes remained
unaffected at the mRNA (Fig. 3A) and protein (Fig. 3B) levels fol-
lowing p38a gene silencing.
We next studied activation of components of the p38 MAPK
pathway in p38a-silenced cells (Fig. 3C). TNFa- and IL-1a-induced
p38 MAPK phosphorylation and MAPKAPK2 phosphorylation was
markedly inhibited in siRNA-targeted cells in which p38a protein
was knocked down (Fig. 3C). Interestingly, MAPKAPK2 protein
expression was also signiﬁcantly reduced in p38a-silenced cells
(Fig. 3C). However, despite the marked loss of p38 and MAPKAPK2
signals, IL-1a-induced HSP27 phosphorylation remained relatively
unaffected (Fig. 3C).
To investigate the effect of selective p38a silencing on IL-6 and
MMP-3 expression, mock- or siRNA-transfected cells were incu-
bated for 4 days prior to stimulation with IL-1a and quantiﬁcation
of mRNA levels and protein secretion after 6 h or 24 h respectively
(Fig 4). IL-6 mRNA expression levels were reduced by 20% in p38a-
silenced cells 6 h after IL-1a stimulation (Fig. 4A). In the same
experiments, IL-1a-induced MMP-3 mRNA levels were reduced
by 65% in p38a-silenced cells. By comparison, p38a siRNA had
no effect on IL-1a-induced IL-1b mRNA levels (110 ± 16% of mock,
P = 0.639, n = 3) or MMP-9 mRNA levels (99 ± 33% of mock,
P = 0.734, n = 3); consistent with our previous demonstration of
insensitivity to the p38a/b inhibitor SB203580 [5,8]. ELISA analysis
of conditioned media (24 h) revealed signiﬁcant inhibition of IL-
1a-induced IL-6 secretion (30%) and IL-1a-induced MMP-3 secre-
tion (50%) in p38a-silenced cells (Fig. 4B).4. Discussion
Previous studies have determined that the most highly ex-
pressed p38 subtype in the adult human heart is p38a, with lower
levels of p38c and p38d, and no detectable p38b [23]. The major
subtypes reported in mouse heart are p38a and p38c [24].
Although it is known that cultured neonatal rat cardiomyocytes ex-
press at least three p38 subtypes (a, b and c [25], the proﬁle of p38
subtype expression in CF has not been previously described. We
found that cultured human CF exhibited a similar proﬁle to that re-
ported for whole heart (i.e. p38a > c > d b). The lack of p38b pro-
tein expression in CF reﬂected the mRNA data and was not due to
antibody inadequacy as control vascular endothelial cells exhibited
demonstrable p38b expression.
In CF, both TNFa and IL-1a selectively stimulated p38a and
p38c phosphorylation, but did not activate p38d. Both p38a and
p38c are activated in the remodeling heart following MI, with
p38 phosphorylation being apparent in both myocytes and ﬁbro-blasts [15]. The increasing evidence that individual p38 MAPK sub-
types regulate distinct cellular functions within the heart offers
potential for CF-speciﬁc therapeutic strategies targeted at the
p38 MAPK pathway [14].
We have previously reported that SB203580, a widely employed
inhibitor of the a and b subtypes of p38 MAPK, can reduce IL-1a-
induced IL-6 mRNA expression levels by 50% [5]. Indeed, several
other studies in rat and mouse CF have also reported that
SB203580 inhibits IL-6 expression in response to a range of inﬂam-
matory and non-inﬂammatory stimuli [14]. Although the inhibi-
tory effect of p38a siRNA (20%) was less than that observed with
pharmacological inhibition, it was consistently observed in cells
from different patients. Overexpression of a dominant negative
p38a mutant also reduced adenosine-induced IL-6 expression in
rat CF by 50% [26]. IL-6 may therefore represent an important
downstream target of the p38a pathway in the heart. Indeed, an
in vivo study on mice with cardiac-speciﬁc overexpression of
p38a revealed upregulation of over 260 genes, and IL-6 was iden-
tiﬁed as a key locus within this p38a signaling network [27].
In comparison with IL-6, much less is known about regulation of
MMP-3 in CF. The MMP-3 gene promoter shares several structural
similarities with the MMP-1 and MMP-9 promoters, including a
TATA box, two AP-1 sites, a PEA3 site and an NF-B binding site
[7]. Although IL-1 induces expression of several MMPs in human
CF (including MMP-1, -3, -9 and -10), only IL-1-induced MMP-3
expression is inhibited by SB203580 [8]. In contrast, IL-1-induced
MMP-3 expression in adult rat CF is reported to be p38-
independent [28], raising the possibility of species-speciﬁc
MMP-3 regulation in CF.
Not only did p38a gene silencing reduce expression of p38a,
but it also reduced protein expression of the downstream substrate
MAPKAPK2. A similar observation was reported in p38a siRNA-
treated HUVECs [29]. Mice with homozygous ablation of the
p38a gene die in utero due to defective placental development
[30], but embryonic ﬁbroblasts cultured from these mice also have
markedly reduced MAPKAPK2 expression due to both transcrip-
tional and post-transcriptional regulation [31]. Thus, MAPKAPK2
expression is dependent on p38a expression. The converse also ap-
plies, as MAPKAPK2 knockout mice exhibit markedly reduced p38a
protein expression [32], highlighting the intricate link between
expression levels of these two molecules.
Although p38 inhibitors have been efﬁcacious in pre-clinical
studies and some early clinical trials, adverse side effects on liver
and CNS function have prevented many progressing beyond Phase
II [33]. This may reﬂect the critical role of p38 signaling in diverse
cellular functions, the importance of p38 feedback signaling loops,
or off-target effects of the inhibitors. Importantly, several trials are
currently underway to investigate the effects of lower doses of p38
inhibitors on cardiovascular disease and its complications [14,34].
By furthering our understanding of the roles of individual p38 sub-
types in cardiac function we may be able to identify alternative
components of the p38 MAPK pathway that are more amenable
to therapeutic intervention for reducing adverse myocardial
remodeling.
In summary, we demonstrated that human CF express the a, c
and d subtypes of p38 MAPK. IL-1a selectively activated both p38a
and p38c, but it was the a subtype of p38 that was important for
IL-1a-induced IL-6 and MMP-3 expression. Hence, targeting p38a
may be an attractive therapeutic approach for reducing speciﬁc as-
pects of the post-MI inﬂammatory response at the level of the CF.
Acknowledgments
This work was supported by a project grant from the British
Heart Foundation (PG/06/012/20287), awarded to N.A.T. and
K.E.P. The funding body was not involved in the design, collection,
424 J.K. Sinﬁeld et al. / Biochemical and Biophysical Research Communications 430 (2013) 419–424analysis or interpretation of data, in the writing of the manuscript
or in the decision to submit the manuscript for publication. We are
grateful to Phil Warburton for cell culture expertise.
References
[1] K.E. Porter, N.A. Turner, Cardiac ﬁbroblasts: at the heart of myocardial
remodeling, Pharmacol. Ther. 123 (2009) 255–278.
[2] N.G. Frangogiannis, C.W. Smith, M.L. Entman, The inﬂammatory response in
myocardial infarction, Cardiovasc. Res. 53 (2002) 31–47.
[3] N.G. Frangogiannis, M.L. Entman, Chemokines in myocardial ischemia, Trends
Cardiovasc. Med. 15 (2005) 163–169.
[4] S.W. van den Borne, J. Diez, W.M. Blankesteijn, J. Verjans, L. Hofstra, J. Narula,
Myocardial remodeling after infarction: the role of myoﬁbroblasts, Nat. Rev.
Cardiol. 7 (2010) 30–37.
[5] N.A. Turner, A. Das, P. Warburton, D.J. O’Regan, S.G. Ball, K.E. Porter,
Interleukin-1a stimulates pro-inﬂammatory cytokine expression in human
cardiac myoﬁbroblasts, Am. J. Physiol. Heart Circ. Physiol. 297 (2009) H1117–
H1127.
[6] N.A. Turner, A. Das, D.J. O’Regan, S.G. Ball, K.E. Porter, Human cardiac
ﬁbroblasts express ICAM-1, E-selectin and CXC chemokines in response to
proinﬂammatory cytokine stimulation, Int. J. Biochem. Cell Biol. 43 (2011)
1450–1458.
[7] N.A. Turner, K.E. Porter, Regulation of myocardial matrix metalloproteinase
expression and activity by cardiac ﬁbroblasts, IUBMB Life 64 (2012) 143–150.
[8] N.A. Turner, P. Warburton, D.J. O’Regan, S.G. Ball, K.E. Porter, Modulatory effect
of interleukin-1a on expression of structural matrix proteins, MMPs and TIMPs
in human cardiac myoﬁbroblasts: role of p38 MAP kinase, Matrix Biol. 29
(2010) 613–620.
[9] G.C. Melendez, J.L. McLarty, S.P. Levick, Y. Du, J.S. Janicki, G.L. Brower,
Interleukin 6 mediates myocardial ﬁbrosis, concentric hypertrophy, and
diastolic dysfunction in rats, Hypertension 56 (2010) 225–231.
[10] R. Mukherjee, J.A. Bruce, D.M. McClister Jr., C.M. Allen, S.E. Sweterlitsch, J.P.
Saul, Time-dependent changes in myocardial structure following discrete
injury in mice deﬁcient of matrix metalloproteinase-3, J. Mol. Cell. Cardiol. 39
(2005) 259–268.
[11] J.E. Clark, N. Sarafraz, M.S. Marber, Potential of p38-MAPK inhibitors in the
treatment of ischaemic heart disease, Pharmacol. Ther. 116 (2007) 192–206.
[12] P. Aukrust, L. Gullestad, T. Ueland, J.K. Damas, A. Yndestad, Inﬂammatory and
anti-inﬂammatory cytokines in chronic heart failure: potential therapeutic
implications, Ann. Med. 37 (2005) 74–85.
[13] J.M. Kyriakis, J. Avruch, Mammalian mitogen-activated protein kinase signal
transduction pathways activated by stress and inﬂammation, Physiol. Rev. 81
(2001) 807–869.
[14] N.A. Turner, Therapeutic regulation of cardiac ﬁbroblast function: targeting
stress-activated protein kinase pathways, Fut. Cardiol. 7 (2011) 673–691.
[15] C.C. Yeh, H. Li, D. Malhotra, S. Turcato, S. Nicholas, R. Tu, B.Q. Zhu, J. Cha, P.M.
Swigart, B.E. Myagmar, A.J. Baker, P.C. Simpson, M.J. Mann, Distinctive ERK and
p38 signaling in remote and infarcted myocardium during post-MI remodeling
in the mouse, J. Cell. Biochem. 109 (2010) 1185–1191.
[16] K.E. Porter, N.A. Turner, D.J. O’Regan, A.J. Balmforth, S.G. Ball, Simvastatin
reduces human atrial myoﬁbroblast proliferation independently of cholesterol
lowering via inhibition of RhoA, Cardiovasc. Res. 61 (2004) 745–755.
[17] N.A. Turner, K.E. Porter, W.H. Smith, H.L. White, S.G. Ball, A.J. Balmforth,
Chronic b2-adrenergic receptor stimulation increases proliferation of human
cardiac ﬁbroblasts via an autocrine mechanism, Cardiovasc. Res. 57 (2003)
784–792.[18] R.S. Mughal, P. Warburton, D.J. O’Regan, S.G. Ball, N.A. Turner, K.E. Porter,
Peroxisome proliferator-activated receptor c-independent effects of
thiazolidinediones on human cardiac myoﬁbroblast function, Clin. Exp.
Pharmacol. Physiol. 36 (2009) 478–486.
[19] N.A. Turner, S.G. Ball, A.J. Balmforth, The mechanism of angiotensin II-induced
extracellular signal-regulated kinase-1/2 activation is independent of
angiotensin AT1A receptor internalisation, Cell. Signalling 13 (2001) 269–277.
[20] P.K. Aley, K.E. Porter, J.P. Boyle, P.J. Kemp, C. Peers, Hypoxic modulation of Ca2+
signaling in human venous endothelial cells. Multiple roles for reactive oxygen
species, J. Biol. Chem. 280 (2005) 13349–13354.
[21] N.A. Turner, R.S. Mughal, P. Warburton, D.J. O’Regan, S.G. Ball, K.E. Porter,
Mechanism of TNFa-induced IL-1a, IL-1b and IL-6 expression in human
cardiac ﬁbroblasts: effects of statins and thiazolidinediones, Cardiovasc. Res.
76 (2007) 81–90.
[22] K.E. Porter, N.A. Turner, D.J. O’Regan, S.G. Ball, Tumor necrosis factor a induces
human atrial myoﬁbroblast proliferation, invasion and MMP-9 secretion:
inhibition by simvastatin, Cardiovasc. Res. 64 (2004) 507–515.
[23] L.E. Lemke, L.J. Bloem, R. Fouts, M. Esterman, G. Sandusky, C.J. Vlahos,
Decreased p38 MAPK activity in end-stage failing human myocardium: p38
MAPKa is the predominant isoform expressed in human heart, J. Mol. Cell.
Cardiol. 33 (2001) 1527–1540.
[24] D. Dingar, C. Merlen, S. Grandy, M.A. Gillis, L.R. Villeneuve, A.M. Mamarbachi,
C. Fiset, B.G. Allen, Effect of pressure overload-induced hypertrophy on the
expression and localization of p38 MAP kinase isoforms in the mouse heart,
Cell. Signalling 22 (2010) 1634–1644.
[25] N.W. Court, C.G. dos Remedios, J. Cordell, M.A. Bogoyevitch, Cardiac expression
and subcellular localization of the p38 mitogen-activated protein kinase
member stress-activated protein kinase-3 (SAPK3), J. Mol. Cell. Cardiol. 34
(2002) 413–426.
[26] W. Feng, Y. Song, C. Chen, Z.Z. Lu, Y. Zhang, Stimulation of adenosine A2B
receptors induces interleukin-6 secretion in cardiac ﬁbroblasts via the PKC-d-
P38 signaling pathway, Br. J. Pharmacol. 159 (2010) 1598–1607.
[27] O. Tenhunen, J. Rysa, M. Ilves, Y. Soini, H. Ruskoaho, H. Leskinen, Identiﬁcation
of cell cycle regulatory and inﬂammatory genes as predominant targets of p38
mitogen-activated protein kinase in the heart, Circ. Res. 99 (2006) 485–493.
[28] R.D. Brown, G.M. Jones, R.E. Laird, P. Hudson, C.S. Long, Cytokines regulate
matrix metalloproteinases and migration in cardiac ﬁbroblasts, Biochem.
Biophys. Res. Commun. 362 (2007) 200–205.
[29] I.M. Evans, G. Britton, I.C. Zachary, Vascular endothelial growth factor induces
heat shock protein (HSP) 27 serine 82 phosphorylation and endothelial
tubulogenesis via protein kinase D and independent of p38 kinase, Cell.
Signalling 20 (2008) 1375–1384.
[30] J.S. Mudgett, J. Ding, L. Guh-Siesel, N.A. Chartrain, L. Yang, S. Gopal, M.M. Shen,
Essential role for p38a mitogen-activated protein kinase in placental
angiogenesis, Proc. Natl. Acad. Sci. USA 97 (2000) 10454–10459.
[31] T. Sudo, K. Kawai, H. Matsuzaki, H. Osada, P38 mitogen-activated protein
kinase plays a key role in regulating MAPKAPK2 expression, Biochem. Biophys.
Res. Commun. 337 (2005) 415–421.
[32] A. Kotlyarov, Y. Yannoni, S. Fritz, K. Laass, J.B. Telliez, D. Pitman, L.L. Lin, M.
Gaestel, Distinct cellular functions of MK2, Mol. Cell. Biol. 22 (2002) 4827–
4835.
[33] P. Cohen, Targeting protein kinases for the development of anti-inﬂammatory
drugs, Curr. Opin. Cell Biol. 21 (2009) 317–324.
[34] M.S. Marber, B. Rose, Y. Wang, The p38 mitogen-activated protein kinase
pathway-A potential target for intervention in infarction, hypertrophy, and
heart failure, J. Mol. Cell. Cardiol. 51 (2011) 485–490.
